Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials. Whereas a role for HDAC1 and -2 in mediating components of the HDAC inhibitor response has been reported, the role of HDAC3 is unknown. Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice. HDAC3 was also maximally expressed in proliferating crypt cells in normal intestine. Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis. Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1. HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation. Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression. However, the magnitude of the effects elicited by silencing of individual Class I HDACs was significantly less than that induced by HDAC inhibitors. These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression. These findings also demonstrate that multiple Class I HDACs are involved in repressing p21 and suggest that the growth-inhibitory and apoptotic effects induced by HDAC inhibitors are probably mediated through the inhibition of multiple HDACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, HDAC3 has been suggested to be involved in carcinogenesis by affecting cell differentiation and apoptosis (52).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [52]
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Intestinal Epithelial Cell Surface Membrane Glycoprotein Synthesis
Weiser, M. M. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44141-0 · Cited by 1,098
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936
Self-citationLost in Transcription: p21 Repression, Mechanisms, and Consequences
Gartel, A. L., & Radhakrishnan, S. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3995 · Cited by 818
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Research works printed but not linked: 9
- Mariadason, 1997, Am. J. Physiol., 272, G705
- Heerdt, 1994, Cancer Res., 54, 3288
- Mei, 2004, Int. J. Oncol., 25, 1509
- Fischle, 2001, Biochem. Cell Biol., 79, 337, 10.1139/o01-116 · DOI · Paper page
- Mariadason, 2001, Cancer Res., 61, 3465
- Sowa, 1999, Cancer Res., 59, 4266
- Mariadason, 2003, Cancer Res., 63, 8791
- Yang, 2001, Cancer Res., 61, 565
- Bailey, 1999, Mol. Endocrinol., 13, 1155, 10.1210/mend.13.7.0305 · doi:10.1210/mend.13.7.0305 · Paper page
Cited by
Items 301–400 of 611
Regulation of VDR Expression in Apc -Mutant Mice, Human Colon Cancers and Adenomas
Giardina, C. A., Nakanishi, M., Khan, A., Kuratnik, A., Xu, W., Brenner, B. M., & Rosenberg, D. W. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0371 · Cited by 24
Killick-Cole, C. L., Singleton, W., Bienemann, A. S., Asby, D. J., Wyatt, M. J., Boulter, L. J., Barua, N. U., & Gill, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176855 · Cited by 27
HDAC inhibitors: Promising agents for leukemia treatment
Deng, Y., Qian, C., & He, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.023 · Cited by 26
The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.
Kuwajima, A., Iwashita, J., Murata, J., & Abé, T. (2007) · PubMed · Cited by 26
Shoombuatong, W., Meewan, I., Mookdarsanit, L., & Schaduangrat, N. (2024) · Methods · doi:10.1016/j.ymeth.2024.08.003 · Cited by 24
Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
Stintzing, S., Kemmerling, R., Kiesslich, T., Alinger, B., Ocker, M., & Neureiter, D. (2011) · BioMed Research International · doi:10.1155/2011/214143 · Cited by 28
“…Nimer [18] common and distinct pathways are involved in the pathogenesis of MDS, which could be summarized by (i) chromosomal/genetic alterations and molecular defects, (ii) disturbance of the microenvironment, and (iii) deregulation of apoptosis as discussed in detail below (see also Figure 1).”
BackgroundBallestrero, A., Garuti, A., Cirmena, G., Rocco, I., Palermo, C., Nencioni, A., Scabini, S., Zoppoli, G. M., Parodi, S., & Patrone, F. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800190956 · Cited by 25
“Several studies have also reported in human CRC the increased expression of different classes of histone deacetylases (HDACs) as a potential mechanism of gene overexpression at transcriptional level [72-75].”
BackgroundSanaei, M., & Kavoosi, F. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.3.795 · Cited by 24
“Our results are consistent with previously published ones reporting that sodium butyrate inhibits HDAC1, HDAC2, and HDAC3 expression in HCT116 and Caco-2 colon cancer cells (Wilson et al., 2006).”
ResultCubilin expression is monoallelic and epigenetically augmented via PPARs
Aseem, S. O., Barth, J. L., Klatt, S. C., Smith, B. T., & Argraves, W. S. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-405 · Cited by 28
“Histone deacetylation catalyzed by HDACs also contributes to the pathogenesis of various diseases including gastric and colorectal cancer [62,63], renal disease such as polycystic kidney disease [64] and macrophage infiltration and fibrotic changes associated with tubulointerstitial injury [65].”
BackgroundAhmad, R., Kumar, B., Pan, K., Dhawan, P., & Singh, A. B. (2017) · Oncotarget · doi:10.18632/oncotarget.21190 · Cited by 28
“Several studies have demonstrated increased expression of the class-I HDACs: HDAC1, HDAC2, and HDAC3, in multiple human cancers, including colon cancer [35, 42, 61].”
BackgroundInfluentialHydrazides as Inhibitors of Histone Deacetylases
Carreiras, M. C., & Marco, J. L. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00541 · Cited by 26
Najem, S. A., Khawaja, G., Hodroj, M. H., & Rizk, S. E. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190313154531 · Cited by 25
Chromatin Regulators with Tumor Suppressor Properties and their Alterations in Human Cancers
Shu, X., Li, L., & Tao, Q. (2012) · Epigenomics · doi:10.2217/epi.12.50 · Cited by 25
Sleiman, S. F., Berlin, J., Basso, M., Karuppagounder, S. S., Rohr, J., & Ratan, R. R. (2011) · Pharmaceuticals · doi:10.3390/ph4081183 · Cited by 23
“Indeed, we provide support for the notion that both HDACi and MTM promote neuroprotection by inhibiting the expression or functions of proteins that mediate transformation such as Myc, HDAC1, HDAC2 and HDAC3 [2,10-13] and by promoting the expression of tumor suppressors such as p21.”
BackgroundNegmeldin, A. T., & Pflum, M. K. H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.033 · Cited by 23
Jin, K., Li, S., Li, X., Zhang, J., Xu, W., & Li, X. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.048 · Cited by 23
Gabrielli, B. G., & Maybury, M. K. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00001-x · Cited by 23
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Steimbach, R. R., Herbst‐Gervasoni, C. J., Merz, A., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200180 · Cited by 22
Gong, W., Wu, R., & Zhang, Y. (2015) · Journal of Computational Chemistry · doi:10.1002/jcc.24203 · Cited by 24
Lv, W., Wei, H.-M., Wang, D.-L., Ni, J., & Sun, F.-L. (2012) · Journal of Cell Science · doi:10.1242/jcs.106336 · Cited by 28
“Hdac3 has also been shown to be upregulated in various tumor types (Spurling et al., 2008; Wu et al., 2010; Wilson et al., 2006).”
BackgroundA genomic approach to predict synergistic combinations for breast cancer treatment
Soldi, R., Cohen, A. L., Cheng, L., Sun, Y., Moos, P. J., & Bild, A. H. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.48 · Cited by 23
“After 4h of incubation at 37°C, the fluorescence was recorded (560(20)Ex/590(10)Em) using a Victor3V 1420 Multilabel Counter (PerkinElmer) plate reader.”
MethodNoor, Z., Noreen, A., & Rashid, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139588 · Cited by 23
Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Sultana, F., Manasa, K. L., Shaik, S. P., Bonam, S. R., & Kamal, Ä. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530094120 · Cited by 22
Pai, J., Hsu, C., Hua, K., Yu, S.-Y., Huang, C.-Y., Chen, C.-N., Liao, C., & Weng, M. (2015) · Molecules · doi:10.3390/molecules20058000 · Cited by 24
“It has been demonstrated that down-regulation HDAC activity gives rise to G1 cell cycle arrest via inducing p21Waf1/Cip1 expression [24,25].”
BackgroundZhang, Y., Zheng, X., Tan, H., Lu, Y., Tao, D., Liu, Y., & Ma, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0462-8 · Cited by 21
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113698 · Cited by 22
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
Sato, A. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s23874 · Cited by 22
HDAC3 regulates stability of estrogen receptor α mRNA
Oie, S., Matsuzaki, K., Yokoyama, W., Murayama, A., & Yanagisawa, J. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.007 · Cited by 21
Paterson, S., Sin, K. L., Tiang, J. M., Minchin, R. F., & Butcher, N. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036202 · Cited by 23
“Of interest, the major class I histones are down-regulated during maturation of intestinal cells along the crypt-villus axis (Wilson et al., 2006).”
BackgroundJo, Y. K., Park, N. Y., Shin, J. H., Jo, D. S., Bae, J., Choi, E. S., Maeng, S., Jeon, H. B., Roh, S. A., Chang, J. W., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12218 · Cited by 20
Padhye, A., Konen, J. M., Rodriguez, B. L., Fradette, J. J., Ochieng, J. K., Diao, L., Wang, J., Lü, W., Solis, L. S., Batra, H., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148392 · Cited by 23
Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
Yang, Q., Falahati, A., Khosh, A., Mohammed, H., Kang, W., Corachán, A., Bariani, M. V., Boyer, T., & Al-Hendy, A. A. (2022) · Cells · doi:10.3390/cells11233801 · Cited by 20
“Histone deacetylases are a class of enzymes that remove acetyl groups from an εN-acetyl-lysine amino acid on histone and govern the chromatin structural dynamics of histones to wrap the DNA more tightly [7,8].”
BackgroundYang, L., Liang, Q., Shen, K., Ma, L., An, N., Deng, W., Fei, Z., & Liu, J. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.02.019 · Cited by 20
Histone deacetylase inhibition as an anticancer telomerase‐targeting strategy
Rahman, R., & Grundy, R. G. (2011) · International Journal of Cancer · doi:10.1002/ijc.26241 · Cited by 21
Zhu, B., Shang, B.-Y., Du, Y., Li, L., Li, L., Xu, X., & Zhen, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14714 · Cited by 20
“HDAC3 is overexpressed in gastric, prostate and colorectal cancer [18]; and high expression level of HDAC1 and HDAC2 correlates with decreased patient survival in colorectal carcinomas [19, 20].”
Colonic transcriptional response to 1α,25(OH)2 vitamin D3 in African- and European-Americans
Alleyne, D., Witonsky, D., Mapes, B. L., Nakagome, S., Sommars, M. A., Hong, E. S., Muckala, K. A., Rienzo, A. D., & Kupfer, S. S. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.02.001 · Cited by 20
“In the colon, HDAC3 was found to be localized to the proliferative zone of the colonic crypt suggesting a role in colon cell maturation and proliferation (63), and is overexpressed in CRC (63).”
BackgroundUba, A. İ., & Yelekçi, K. (2017) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1701-26 · Cited by 19
Luna‐Coronell, J. A., Sergelen, K., Hofer, P., Gyurján, I., Brezina, S., Hettegger, P., Leeb, G., Mach, K., Gsur, A., & Weinhäusel, A. (2018) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2017.10.002 · Cited by 21
“For instance, HDAC1, which plays a role in cell proliferation, survival, and inhibition of differentiation, shows higher antigenic reactivity in our study, which has been corroborated in CRC tumor studies [60,61].”
ResultBuckwalter, J. M., Chan, W. H.-C., Shuman, L., Wildermuth, T., Ellis-Mohl, J., Walter, V., Warrick, J. I., Wu, X., Kaag, M. G., Raman, J. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102599 · Cited by 20
Histone deacetylase inhibitors from microorganisms: the Astellas experience
Masuoka, Y., Shindoh, N., & Inamura, N. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8595-8_7 · Cited by 21
Tavares, M. T., de Almeida, L. C., Kronenberger, T., Ferreira, G. M., de Divitiis, T. F., Toledo, M. F. Z. J., Hassimotto, N. M. A., Machado‐Neto, J. A., Costa-Lotufo, L. V., & Parise‐Filho, R. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116085 · Cited by 21
FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma
Lou, T., Liu, C., Qu, H., Zhang, Z., Wang, S., & Zhuang, H. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-021-03224-3 · Cited by 22
“HDAC3 plays an important role in the progression of malignant tumors, especially in proliferation [5], apoptosis [6], metastasis [7], angiogenesis [8] and anticancer drug resistance [9].”
BackgroundMayer, M., Berger, A., Leischner, C., Renner, O., Burkard, M., Böcker, A., Noor, S., Weiland, T., Weiß, T. S., Busch, C., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15040438 · Cited by 20
“Elevated levels of several HDACs have been reported in colon cancer [41] and hepatocellular cancer [42–44], while downregulation of specific HDACs inhibits growth of cancer cells in vitro and intestinal tumorigenesis in vivo [45,46].”
BackgroundRoostaee, A., Guezguez, A., Beauséjour, M., Simoneau, A., Vachon, P. H., Levy, E. H., & Beaulieu, J. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25274 · Cited by 21
Ouaïssi, M., Giger-Pabst, U., Sielezneff, I., Pirró, N., Sastre, B., & Ouaissi, A. (2010) · BioMed Research International · doi:10.1155/2011/315939 · Cited by 20
“For example, overexpression of HDAC1 has been reported in gastric [12] and HDAC2 and HDAC3 in colorectal cancer [13, 14].”
BackgroundHuang, E., Zhao, Y., Chen, G., Baek, S. J., McEntee, M. F., Minkin, S. C., Biggerstaff, J., & Whelan, J. N. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-68 · Cited by 19
“HDACs 1–4 have been shown to be involved in the repression of p21 expression [25-27].”
Vitamin D resistance and colon cancer prevention
Giardina, C. A., Madigan, J. P., Tierney, C. A., Brenner, B. M., & Rosenberg, D. W. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr301 · Cited by 20
Zeglis, B. M., Pillarsetty, N., Divilov, V., Blasberg, R., & Lewis, J. S. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.12.008 · Cited by 18
Liou, S.-F., Hua, K., Hsu, C., & Weng, M. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.03.018 · Cited by 19
Fu, S.-C., Qu, J., Li, L.-X., Yang, X., Li, Y., & Zuo, X. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad132 · Cited by 22
Epigenetic Effects of Blackberry Extract on Human Colorectal Cancer Cells
Tatar, M., Varedi, M., & Naghibalhossaini, F. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1952454 · Cited by 22
“Consistent overexpression of different HDAC enzymes including HDACs 1–4 have been reported in colon cancers and the up-regulation has been shown to occur in the early stage of carcinogenesis (11,37,38).”
BackgroundAnticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells
Tsai, F.-L., Huang, H.-L., Lai, M.-J., Liou, J., Pan, S., & Yang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612588 · Cited by 19
Nardilysin controls intestinal tumorigenesis through HDAC1/p53–dependent transcriptional regulation
Kanda, K., Sakamoto, J., Matsumoto, Y., Ikuta, K., Goto, N., Morita, Y., Ohno, M., Nishi, K., Eto, K., Kimura, Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.91316 · Cited by 17
Ishola, A. A., & Adewole, K. E. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04689-8 · Cited by 18
Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy
Algamas‐Dimantov, A., Yehuda‐Shnaidman, E., Peri, I., & Schwartz, B. (2013) · Cellular Oncology · doi:10.1007/s13402-012-0123-3 · Cited by 20
Short-chain fatty acid–mediated effects on erythropoiesis in primary definitive erythroid cells
Bhatia, H., Hallock, J. L., Dutta, A., Karkashon, S., Sterner, L., Miyazaki, T., Dean, A., & Little, J. A. (2009) · Blood · doi:10.1182/blood-2008-09-171728 · Cited by 18
Xie, S., Leng, J., Zhao, S., Zhu, L., Zhang, M., Ning, M., Zhao, B., Kong, L., & Yin, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116301 · Cited by 18
Oh, S.-Y., Balch, C. G., Cliff, R. L., Sharma, B. S., Boermans, H. J., Swamy, H. V. L. N., Quinton, V. M., & Karrow, N. A. (2013) · Mycotoxin Research · doi:10.1007/s12550-013-0174-y · Cited by 16
“Inhibited JMJD-3 expression would likely induce cell proliferation (Wilson et al. 2006; Wong et al. 2011), yet our previous study determined that PA+OTA synergistically inhibited the proliferation of BoMacs (Oh et al.”
BackgroundResultA series of camptothecin prodrugs exhibit HDAC inhibition activity
Zhu, Q., Yu, X., Shen, Q., Zhang, Q., Su, M., Zhou, Y., Li, J. X., Chen, Y., & Lu, W. P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.08.008 · Cited by 17
Effects of 10-Hydroxy-2-decenoic acid on the development of honey bee (Apis mellifera) larvae
Wang, W. X., Tian, L. Q., Huang, Q., Wu, X. B., & Zeng, Z. J. (2014) · Journal of Apicultural Research · doi:10.3896/ibra.1.53.1.19 · Cited by 22
“It has been reported that silencing of HDAC3 stimulates p21 promoter activity and expression level (Wilson et al., 2006).”
BackgroundTurgeon, N., Valiquette, C., Blais, M., Routhier, S., Seidman, E. G., & Asselin, C. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21544 · Cited by 17
“HDAC1 and HDAC3 were ubiquitously expressed in human carcinoma Caco-2/15 and in crypt cells, as observed before [Wilson et al., 2006].”
Organosulfur Compounds in Colorectal Cancer Prevention and Progression
McAlpine, P., Fernández, J., Villar, C. J., & Lombó, F. (2024) · Nutrients · doi:10.3390/nu16060802 · Cited by 19
“HDACs (histone deacetylase enzymes) are known to be overexpressed in several cancers and their downregulation is associated with cell cycle arrest and apoptosis [54].”
BackgroundStochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat
Omari, N. E., Khalid, A., Makeen, H. A., Alhazmi, H. A., Albratty, M., Mohan, S., Tan, C. S., Ming, L. C., Chook, J. B., & Bouyahya, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33052 · Cited by 18
Sodium butyrate restores ASC expression and induces apoptosis in LS174T cells
Zhang, S., Bai, J., Ren, S., Wang, R., ZHANG, L., & Zuo, Y. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1156 · Cited by 16
“The SCFA family of transcriptional co-repressors, such as sodium butyrate (NaBu), induces cell cycle arrest, markers of cell differentiation and apoptosis in colon cancer cell lines in vitro (17).”
Li, N., Tie, X., Liu, P., Zhang, Y., Ren, H., Gao, X., & Xu, Z. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.2.685 · Cited by 19
“Over-expression of HDAC3 in colon cancer cells can lead to the inhibition of p21 expression, and HDAC3 quiescence can promote the expression of p21 (Wilson et al., 2006).”
BackgroundDamante, G. (2010) · Oncology Reports · doi:10.3892/or.2010.1075 · Cited by 22
Zhong, S., Fan, Y., Wu, B., Wang, Y., Jiang, S., Ge, J., Hua, C., Zhao, G., Chen, Y. X., & Xu, H. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.07.076 · Cited by 16
Olzscha, H., Bekheet, M., Sheikh, S., & Thangue, N. B. L. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_19 · Cited by 17
Mao, P., He, W.-B., Mai, X., Feng, L., Li, N., Liao, Y., Zhu, C.-S., Li, J., Chen, T., Liu, S.-H., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116599 · Cited by 15
Jain, R., & Epstein, J. A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-44087-8_18 · Cited by 18
Fan, W., Huang, J., & Xiao, H. (2015) · Europe PMC (PubMed Central) · Cited by 17
Stebe-Frick, S., Ostaff, M. J., Stange, E. F., Malek, N. P., & Wehkamp, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-31125-x · Cited by 16
Gao, D., Xu, M., Zhang, Y., Du, Y., Gao, J., Gong, Y.-F., Man, X.-H., Wu, H., Jin, J., Xu, G.-M., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181db0086 · Cited by 16
Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases
Inchiosa, M. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198514 · Cited by 15
Epigenetic Drug Therapy in the Treatment of Colorectal Cancer
Parizadeh, S. M., Esfehani, R. J., Ghandehari, M., Seifi, S., Parizadeh, S. M. R., Moetamani‐Ahmadi, M., Hassanian, S. M., Khazaei, M., Ghayour‐Mobarhan, M., Ferns, G. A., et al. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730151904 · Cited by 15
“colon cancer, breast and gastric cancer while overexpression of HDAC2 is mostly seen in cervical and colorectal carcinoma with loss of APC expression [27, 29-31].”
BackgroundCostanzo, G., Buccheri, R., Cosentino, G., Reale, C., Zuccalà, S., Marrazzo, A., Amata, E., Rescifina, A., & Pasquinucci, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117998 · Cited by 15
Yang, Y., Liu, Q., Wang, X., & Gou, S.-H. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129305 · Cited by 15
Imperative connotation of SODs in cancer: Emerging targets and multifactorial role of action
Panda, B., Tripathy, A., Patra, S., Kullu, B., Tabrez, S. S. M., & Jena, M. (2024) · IUBMB Life · doi:10.1002/iub.2821 · Cited by 15
“148 Similarly, enhanced HDAC3 has been visualized in many solid cancers, such as lung, breast, pancreatic, liver, and colon cancer 151,152 (Figure 5 and Table 1).”
Wu, J., Wang, X., Yao, Y., Du, N., Duan, L., & Gong, P. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107556 · Cited by 14
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy
Islam, S., Espitia, C. M., Persky, D. O., Carew, J. S., & Nawrocki, S. T. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002297 · Cited by 15
The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells
Shin, M. W., Kim, S., Yang, H. C., Yim, S. K., Seo, S. Y., Lee, S. T., Kim, H.-K., & Kim, S. (2021) · Anticancer Research · doi:10.21873/anticanres.15240 · Cited by 14
HDAC3 Is Required for Posterior Lateral Line Development in Zebrafish
He, Y., Wang, Z., Sun, S., Tang, D., Li, W., Chai, R., & Li, H. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9433-6 · Cited by 14
“49], cell viability [50], and cell apoptosis [51].”
BackgroundKim, H., Kim, Y., Goh, H., & Jeoung, D. (2016) · Molecules and Cells · doi:10.14348/molcells.2016.2244 · Cited by 13
“In agreement with these reports, it has been shown that HDAC3 appeared to be up-regulated and to repress the tumor suppressor gene p21 in colorectal cancer cells (Wilson et al., 2006).”
BackgroundMaking Sense of HDAC2 Mutations in Colon Cancer
Mariadason, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.039 · Cited by 14
Self-citationChen, C., Fang, J., Chen, C., Chuang, W., Leu, Y., Ueng, S., Wei, L.-S., Cheng, S.-F., Hsueh, C., & Wang, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01319 · Cited by 17
Zhang, Y., Yu, G., Wang, D., Hu, Y., & Lei, W. (2011) · Toxicon · doi:10.1016/j.toxicon.2011.03.008 · Cited by 13
“It was recently reported that HDAC inhibitors can induce strong apoptosis in cancer cells, and also suppress tumor growth and progression, induce differentiation of transformed cells and inhibit tumor angiogenesis and invasion in vivo (Bolden et al., 2006; Minucci and Pelicci, 2006; Wilson, 2006).”
BackgroundHe, F., Liu, Q., Liu, H., Pei, Q., & Zhu, H. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23522 · Cited by 14
“It was reported that HDAC3 acted as a regulator of colon cell maturation.(51) Also, high expression of HDAC3 could enhance colon cell proliferation and differentiation.”
BackgroundPatil, H., Wilks, C., Gonzalez, R. W., Dhanireddy, S., Conrad-Webb, H., & Bergel, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.643874 · Cited by 16
“RNAi-mediated knockdown of HDAC3 in HeLa cells causes cell cycle arrest in G2/M phase (4, 32), loss of H3S10 phosphorylation (a mitosis marker), and impaired mitotic progression such as incomplete chromosomal condensation and “lagging” chromosomes (4).”
BackgroundThe Histone Deacetylase Inhibitor MGCD0103 Has Both Deacetylase and Microtubule Inhibitory Activity
Chia, K., Beamish, H., Jafferi, K., & Gabrielli, B. G. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065169 · Cited by 14
Therapeutic regulation of epigenetics in cancer treatment through drug delivery systems
Su, B., Li, S., Geng, S., Brambilla, D., Sun, R., Sun, T., & Jiang, C. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102251 · Cited by 15
Stanilov, N., Miteva, L. D., Cirovski, G., & Stanilova, S. A. (2016) · Współczesna Onkologia · doi:10.5114/wo.2016.65605 · Cited by 18
“Although the upregulated expression of HDAC3 in colon neoplasia has been well documented [34] data for transcriptional activation of the HDAC3 gene in mononuclear cells of CRC patients are not available.”
BackgroundLim, J. Y., & Kwan, H. Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.80788 · Cited by 15
“The role of HDACs in cancer was also demonstrated in several cancers such as cervical [95], colon [96], and gastric cancer [97].”
BackgroundHigh Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
Zhao, W., Jiang, X., Weisenthal, K., Ma, J., Botticelli, E. M., Zhou, Y., Hedley‐Whyte, E. T., Wang, B., Swearingen, B., Soberman, R. J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.875122 · Cited by 12
“In colon cancer cells, silencing of HDAC3 expression by RNA interference (RNAi) resulted in growth suppression, accompanied by increased expression of p21 and apoptosis (39).”
BackgroundExpression of histone deacetylase-1 and p300 in aristolochic acid nephropathy models
Tian, Y., Yang, Y., Gao, L., Zhao, H., Peng, X., Zhang, Z., & Guo-juan, W. (2014) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2014.920448 · Cited by 12
“Some studies show that HDAC1 is highly expressed in prostate and colon cancer (Wilson et al., 2006), suggesting that HDAC1 is associated with fibrosis (Marumo et al., 2009).”
BackgroundPufahl, L., Katryniok, C., Schnur, N., Sorg, B. L., Metzner, J., Grez, M., & Steinhilber, D. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01420.x · Cited by 13
“Butyrate has also been found to induce 5-LO expression in colorectal carcinoma Caco-2 cells and silencing of HDAC3 and other class I HDACs in colon cancer cell lines leads to cell growth inhibition, differentiation and apoptosis [23].”
BackgroundYeo, S., Kim, D. Y., Kim, K., Ku, J., Kim, J.-S., Cho, M.-J., Kim, E. S., & Yoo, B. C. (2012) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182505080 · Cited by 12
Adewole, K. E., Ishola, A. A., & Olaoye, I. F. (2022) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-021-00191-y · Cited by 12
“Specific examples are seen in the regulation of cell cycle by HDACs 1, and 3, over expression of HDAC1 in gastric, breast, prostate and colon cancers [20, 21], over expression of HDAC2 in gastric, cervical and colorectal cancers [22, 23], overexpression of HDAC3 in colon cancer [21], over activities of HDAC2 and HDAC3…”
BackgroundLipids, LXRs and prostate cancer: Are HDACs a new link?
Hoang, J.-J., Baron, S., Volle, D. H., Lobaccaro, J. A., & Trousson, A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.005 · Cited by 14
Photoreactive “Nanorulers” Detect a Novel Conformation of Full Length HDAC3-SMRT Complex in Solution
Abdelkarim, H., Brunsteiner, M., Neelarapu, R., Bai, H., Madriaga, A., van Breemen, R. B., Blond, S. Y., Gaponenko, V., & Petukhov, P. A. (2013) · ACS Chemical Biology · doi:10.1021/cb400601g · Cited by 14
Wong, J. C., Guo, L., Peng, Z., Zhang, W., Zhang, N., Lai, W., Zhang, Z., Zhang, C., Zhang, X., Song, S., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.11.063 · Cited by 12
Metadata
- Authors
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Kyoto Prefectural University of Medicine (JP)
- Vall d'Hebron Institut de Recerca (ES)
- Corresponding author
- Mariadason, John M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 19
- Pages
- 13548-13558
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2105095164
- Semantic Scholar
- c2db47db00c10ecf03aae7c6c6f1c3b194c81502
- Cited by
- 575
- References
- 43
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 31 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 30 · 2019: 26 · 2018: 27 · 2017: 30 · 2016: 30 · 2015: 38 · 2014: 32 · 2013: 40 · 2012: 28
- FWCI
- 13.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5273 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088104, R01CA100823, CA88104-04, CA100823-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, class I HDACs, colon cancer, histone deacetylase inhibitors, apoptosis, alkaline phosphatase, duodenal adenoma, crypt cells, gene silencing, tumor suppressor
- MeSH terms
- Cell Differentiation, Colon, Colonic Neoplasms, Histone Deacetylases, Humans, Time Factors, Down-Regulation, Up-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, Caco-2 Cells, Gene Silencing, HCT116 Cells, Cell Proliferation, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.